Arcus Biosciences’ (RCUS) Overweight Rating Reaffirmed at Cantor Fitzgerald
Arcus Biosciences (NYSE:RCUS – Get Free Report)‘s stock had its “overweight” rating reissued by Cantor Fitzgerald in a note issued to investors on Friday, Benzinga reports. A number of other equities analysts have also commented on RCUS. Citigroup raised their price objective on Arcus Biosciences from $36.00 to $38.00 and gave the stock a “buy” […]
More Stories
Invesco Russell 1000 Dynamic Multifactor ETF (OMFL) to Issue Dividend of $0.11 on September 27th
Invesco Russell 1000 Dynamic Multifactor ETF (BATS:OMFL – Get Free Report) announced a dividend on Friday, September 20th, NASDAQ reports....
Cambria Global Momentum ETF (BATS:GMOM) Raises Dividend to $0.36 Per Share
Cambria Global Momentum ETF (BATS:GMOM – Get Free Report) declared a dividend on Friday, September 20th, NASDAQ reports. Shareholders of...
Invesco Short Duration Bond ETF (ISDB) to Issue Dividend of $0.11 on September 27th
Invesco Short Duration Bond ETF (BATS:ISDB – Get Free Report) announced a dividend on Friday, September 20th, NASDAQ reports. Investors...
Sudan: UN chief alarmed at full-scale assault on El Fasher
The UN Secretary-General is gravely alarmed by reports of a full-scale assault on El Fasher by the Rapid Support Forces...
Lennar (NYSE:LEN) Issues Quarterly Earnings Results, Beats Estimates By $0.28 EPS
Lennar (NYSE:LEN – Get Free Report) posted its quarterly earnings results on Thursday. The construction company reported $3.90 earnings per...
Secret Service, Homeland Security Sued Over Records Related to Trump Assassination Attempt
By Jack Phillips A lawsuit was filed against the U.S. Secret Service and Department of Homeland Security (DHS) in a...